Investigational Drug Information for RAD1901
✉ Email this page to a colleague
What is the development status for investigational drug RAD1901?
RAD1901 is an investigational drug.
There have been 6 clinical trials for RAD1901.
The most recent clinical trial was a Phase 2 trial, which was initiated on May 10th 2019.
The most common disease conditions in clinical trials are Breast Neoplasms, Hot Flashes, and [disabled in preview]. The leading clinical trial sponsors are Radius Pharmaceuticals, Inc., Radius Health, Inc., and Context Therapeutics Inc.
There are fourteen US patents protecting this investigational drug and one hundred and forty-seven international patents.
Summary for RAD1901
| US Patents | 14 |
| International Patents | 147 |
| US Patent Applications | 128 |
| WIPO Patent Applications | 101 |
| Japanese Patent Applications | 15 |
| Clinical Trial Progress | Phase 2 (2019-05-10) |
| Vendors | 21 |
Recent Clinical Trials for RAD1901
| Title | Sponsor | Phase |
|---|---|---|
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer | Context Therapeutics Inc. | Phase 1/Phase 2 |
| Phase 3 Trial of Elacestrant vs. Standard of Care for the Treatment of Patients With ER+/HER2- Advanced Breast Cancer | Radius Pharmaceuticals, Inc. | Phase 3 |
| Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer | Radius Health, Inc. | Phase 1 |
Clinical Trial Summary for RAD1901
Top disease conditions for RAD1901
Top clinical trial sponsors for RAD1901
US Patents for RAD1901
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| RAD1901 | ⤷ Try a Trial | Method of treating cancer using selective estrogen receptor modulators | Duke University (Durham, NC) | ⤷ Try a Trial |
| RAD1901 | ⤷ Try a Trial | Benzothiophene estrogen receptor modulators | G1 Therapeutics, Inc. (Research Park Triangle, NC) | ⤷ Try a Trial |
| RAD1901 | ⤷ Try a Trial | Polymorphic forms of RAD1901-2HCL | Radius Pharmaceuticals, Inc. (Waltham, MA) | ⤷ Try a Trial |
| RAD1901 | ⤷ Try a Trial | Method of treating cancer using selective estrogen receptor modulators | Duke University (Durham, NC) | ⤷ Try a Trial |
| RAD1901 | ⤷ Try a Trial | Benzothiophene estrogen receptor modulators | G1 Therapeutics, Inc. (Research Park Triangle, NC) | ⤷ Try a Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for RAD1901
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| RAD1901 | Canada | CA2943611 | 2034-03-28 | ⤷ Try a Trial |
| RAD1901 | European Patent Office | EP3122426 | 2034-03-28 | ⤷ Try a Trial |
| RAD1901 | European Patent Office | EP3834824 | 2034-03-28 | ⤷ Try a Trial |
| RAD1901 | European Patent Office | EP4035664 | 2034-03-28 | ⤷ Try a Trial |
| RAD1901 | World Intellectual Property Organization (WIPO) | WO2015149045 | 2034-03-28 | ⤷ Try a Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
